BR0313425A - Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial - Google Patents
Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercialInfo
- Publication number
- BR0313425A BR0313425A BR0313425-3A BR0313425A BR0313425A BR 0313425 A BR0313425 A BR 0313425A BR 0313425 A BR0313425 A BR 0313425A BR 0313425 A BR0313425 A BR 0313425A
- Authority
- BR
- Brazil
- Prior art keywords
- macrolide compound
- ocular allergy
- ophthalmic composition
- commercial package
- allergy treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 3
- 208000026935 allergic disease Diseases 0.000 title abstract 3
- 230000007815 allergy Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003120 macrolide antibiotic agent Substances 0.000 title abstract 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 abstract 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229960001967 tacrolimus Drugs 0.000 abstract 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40206102P | 2002-08-09 | 2002-08-09 | |
| PCT/JP2003/010105 WO2004014373A1 (en) | 2002-08-09 | 2003-08-08 | Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313425A true BR0313425A (pt) | 2005-07-05 |
Family
ID=31715781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313425-3A BR0313425A (pt) | 2002-08-09 | 2003-08-08 | Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050239813A1 (enExample) |
| EP (1) | EP1536793A1 (enExample) |
| JP (2) | JP2005536531A (enExample) |
| KR (1) | KR20050054913A (enExample) |
| CN (1) | CN1674896A (enExample) |
| AU (1) | AU2003256068A1 (enExample) |
| BR (1) | BR0313425A (enExample) |
| CA (1) | CA2495103A1 (enExample) |
| MX (1) | MXPA05001575A (enExample) |
| WO (1) | WO2004014373A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040019034A (ko) * | 2001-07-06 | 2004-03-04 | 수캄포 아게 | 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물 |
| US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| JP2007505932A (ja) | 2003-09-18 | 2007-03-15 | マクサイト， インコーポレイテッド | 経強膜送達 |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| AU2006213673A1 (en) | 2005-02-09 | 2006-08-17 | Santen Pharmaceutical Co., Ltd. | Formulations for ocular treatment |
| CA2615990A1 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
| CN1965825B (zh) * | 2005-11-17 | 2011-07-06 | 洪晶 | 一种治疗眼部免疫性疾病及抑制增殖、新生血管的眼表用药 |
| BRPI0707612B8 (pt) | 2006-02-09 | 2021-05-25 | Macusight Inc | vaso lacrado e formulações líquidas contidas no mesmo |
| US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| KR100891313B1 (ko) | 2007-08-17 | 2009-03-31 | (주) 제노텍 | 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법 |
| US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| KR101632042B1 (ko) * | 2014-06-30 | 2016-06-21 | 주식회사 인트론바이오테크놀로지 | Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE66485B1 (en) * | 1989-07-05 | 1996-01-10 | Fujisawa Pharmaceutical Co | Aqueous liquid composition for external use |
| CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
| US5514686A (en) * | 1991-04-26 | 1996-05-07 | Fujisawa Pharmaceutical Co., Ltd. | Use of macrolide compounds for eye diseases |
| US7063857B1 (en) * | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| HK1043321B (en) * | 1999-04-30 | 2005-07-15 | 苏坎波公司 | Use of macrolide compounds for the treatment of dry eye |
| AR033151A1 (es) * | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| KR20040019034A (ko) * | 2001-07-06 | 2004-03-04 | 수캄포 아게 | 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물 |
| WO2003043650A1 (en) * | 2001-11-21 | 2003-05-30 | Sucampo Ag | Use of fk506 and analogues for treating allergic diseases |
-
2003
- 2003-08-08 US US10/523,842 patent/US20050239813A1/en not_active Abandoned
- 2003-08-08 MX MXPA05001575A patent/MXPA05001575A/es not_active Application Discontinuation
- 2003-08-08 EP EP03784593A patent/EP1536793A1/en not_active Withdrawn
- 2003-08-08 KR KR1020057002129A patent/KR20050054913A/ko not_active Withdrawn
- 2003-08-08 AU AU2003256068A patent/AU2003256068A1/en not_active Abandoned
- 2003-08-08 BR BR0313425-3A patent/BR0313425A/pt not_active Application Discontinuation
- 2003-08-08 CN CNA038190176A patent/CN1674896A/zh active Pending
- 2003-08-08 CA CA002495103A patent/CA2495103A1/en not_active Abandoned
- 2003-08-08 JP JP2004527368A patent/JP2005536531A/ja active Pending
- 2003-08-08 WO PCT/JP2003/010105 patent/WO2004014373A1/en not_active Ceased
-
2010
- 2010-09-10 JP JP2010203075A patent/JP2011012071A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20050239813A1 (en) | 2005-10-27 |
| JP2005536531A (ja) | 2005-12-02 |
| CA2495103A1 (en) | 2004-02-19 |
| MXPA05001575A (es) | 2005-08-19 |
| AU2003256068A1 (en) | 2004-02-25 |
| JP2011012071A (ja) | 2011-01-20 |
| KR20050054913A (ko) | 2005-06-10 |
| CN1674896A (zh) | 2005-09-28 |
| WO2004014373A1 (en) | 2004-02-19 |
| EP1536793A1 (en) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0313425A (pt) | Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial | |
| CU23423B7 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea | |
| CO5631443A2 (es) | Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales | |
| CL2004000788A1 (es) | Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d | |
| AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
| BRPI0415971A (pt) | método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
| BR0209518A (pt) | Novos derivados arilheteroalquilamina | |
| AU2002331391A1 (en) | N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| SV2009003288A (es) | Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| NO20062591L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
| BRPI0408024A (pt) | combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase | |
| TW200700392A (en) | Novel compounds | |
| NO20072089L (no) | Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav | |
| BRPI0409882A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| TW200740434A (en) | A prophylactic and/or therapeutic agent for for sleep disorders | |
| BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| NZ509105A (en) | Cyclic 24-membered depsipeptides for controlling ectoparasites | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |